Allergan PLCFind Ratings Reports
ALLERGAN PLC's gross profit margin for the third quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. ALLERGAN PLC is extremely liquid. Currently, the Quick Ratio is 3.71 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 15.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||3622.2||3469.5|
|Net Income ($mil)||15220.0||5301.2|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||27392.3||2070.9|
|Total Assets ($mil)||143607.7||142816.3|
|Total Debt ($mil)||32770.0||42683.5|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||88.87||90.06|
|Return on Assets||9.98||2.67|
|Return on Equity||-2.17||-4.26|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||381.5||394.0|
|Div / share||0.0||0.0|
|Book value / share||235.19||196.63|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||5252335.0||3192715.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.92 indicates a significant discount versus the S&P 500 average of 2.84 and a significant discount versus the industry average of 65.26. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ALLERGAN PLC proves to trade at a discount to investment alternatives within the industry.
|AGN NM||Peers 27.12||AGN 27.41||Peers 18.93|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AGN's P/E is negative making this valuation measure meaningless.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AGN is trading at a significant premium to its peers.
|AGN 13.58||Peers 14.42||AGN NA||Peers 0.50|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
AGN is trading at a premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AGN 0.92||Peers 65.26||AGN 52.32||Peers -14.61|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AGN is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AGN is expected to have an earnings growth rate that significantly exceeds its peers.
|AGN 5.54||Peers 12.47||AGN 29.63||Peers 5.05|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AGN is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
AGN has a sales growth rate that significantly exceeds its peers.